Want to take quizzes and track your credits?
Can electronic medical records be used to reliably categorize risk of future hypoglycemia-related emergency department or hospital use in patients with type 2 diabetes?
We developed and validated a risk stratification tool that categorized patients’ 12-month risk of hypoglycemia-related utilization using only 6 electronic medical record–based inputs (patient history of hypoglycemia-related utilization, insulin use, sulfonylurea use, emergency department use, chronic kidney disease, and age). Tool performance was validated in 2 fully independent populations.
This hypoglycemia risk stratification tool could facilitate efficient targeting of population management interventions to reduce hypoglycemia risk and improve patient safety.
Hypoglycemia-related emergency department (ED) or hospital use among patients with type 2 diabetes (T2D) is clinically significant and possibly preventable.
To develop and validate a tool to categorize risk of hypoglycemic-related utilization in patients with T2D.
Design, Setting, and Participants
Using recursive partitioning with a split-sample design, we created a classification tree based on potential predictors of hypoglycemia-related ED or hospital use. The resulting model was transcribed into a tool for practical application and tested in 1 internal and 2 fully independent, external samples. Development and internal testing was conducted in a split sample of 206 435 patients with T2D from Kaiser Permanente Northern California (KPNC), an integrated health care system. The tool was externally tested in 1 335 966 Veterans Health Administration and 14 972 Group Health Cooperative patients with T2D.
Based on a literature review, we identified 156 candidate predictor variables (prebaseline exposures) using data collected from electronic medical records.
Main Outcomes and Measures
Hypoglycemia-related ED or hospital use during 12 months of follow-up.
The derivation sample (n = 165 148) had a mean (SD) age of 63.9 (13.0) years and included 78 576 (47.6%) women. The crude annual rate of at least 1 hypoglycemia-related ED or hospital encounter in the KPNC derivation sample was 0.49%. The resulting hypoglycemia risk stratification tool required 6 patient-specific inputs: number of prior episodes of hypoglycemia-related utilization, insulin use, sulfonylurea use, prior year ED use, chronic kidney disease stage, and age. We categorized the predicted 12-month risk of any hypoglycemia-related utilization as high (>5%), intermediate (1%-5%), or low (<1%). In the internal validation sample, 2.0%, 10.7%, and 87.3% were categorized as high, intermediate, and low risk, respectively, with observed 12-month hypoglycemia-related utilization rates of 6.7%, 1.4%, and 0.2%, respectively. There was good discrimination in the internal validation KPNC sample (C statistic = 0.83) and both external validation samples (Veterans Health Administration: C statistic = 0.81; Group Health Cooperative: C statistic = 0.79).
Conclusions and Relevance
This hypoglycemia risk stratification tool categorizes the 12-month risk of hypoglycemia-related utilization in patients with T2D using only 6 inputs. This tool could facilitate targeted population management interventions, potentially reducing hypoglycemia risk and improving patient safety and quality of life.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Corresponding Author: Andrew J. Karter, PhD, Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612 (firstname.lastname@example.org).
Accepted for Publication: June 20, 2017.
Published Online: August 21, 2017. doi:10.1001/jamainternmed.2017.3844
Author Contributions: Dr Karter had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Karter, Warton, Lipska, Moffet, Huang, Miller.
Acquisition, analysis, or interpretation of data: Karter, Warton, Lipska, Ralston, Moffet, Jackson, Miller.
Drafting of the manuscript: Karter, Warton, Jackson.
Critical revision of the manuscript for important intellectual content: Karter, Warton, Lipska, Ralston, Moffet, Huang, Miller.
Statistical analysis: Karter, Warton, Miller.
Obtained funding: Karter, Moffet.
Administrative, technical, or material support: Karter, Ralston, Moffet, Jackson, Miller.
Supervision: Karter, Ralston, Huang.
Conflict of Interest Disclosures: The National Institutes of Health supplied additional funding for our hypoglycemia-related research (NIDDK R01DK103721, R01DK081796). Drs Karter and Huang are also supported by the NIDDK Centers for Diabetes Translational Research (P30 DK092924 and P30 DK092949, respectively). Dr Huang was supported by K24 DK105340. Dr Lipska receives support from the Centers for Medicare & Medicaid Services to develop and maintain publicly reported quality measures, and from the Yale Claude D. Pepper Older Americans Independence Center (P30AG021342) and the National Institute on Aging through the Paul Beeson Career Development Award (K23AG048359). No other disclosures are reported.
Funding/Support: This project was funded by the US Food and Drug Administration (FDA BAA-13 00119).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
You currently have no searches saved.